Cancer immunotherapy

Breaking the barriers to harvest the crop

Andrew Mark Pardoll, James Allison

Research output: Contribution to journalArticle

Abstract

Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.

Original languageEnglish (US)
Pages (from-to)887-892
Number of pages6
JournalNature Medicine
Volume10
Issue number9
DOIs
StatePublished - Sep 2004

Fingerprint

Public-Private Sector Partnerships
Immunology
National Cancer Institute (U.S.)
United States Food and Drug Administration
Allergy and Immunology
Immunotherapy
Crops
Research Personnel
Industry
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cancer immunotherapy : Breaking the barriers to harvest the crop. / Pardoll, Andrew Mark; Allison, James.

In: Nature Medicine, Vol. 10, No. 9, 09.2004, p. 887-892.

Research output: Contribution to journalArticle

@article{a1f1e7f97b784e679499c9dca97dc658,
title = "Cancer immunotherapy: Breaking the barriers to harvest the crop",
abstract = "Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.",
author = "Pardoll, {Andrew Mark} and James Allison",
year = "2004",
month = "9",
doi = "10.1038/nm0904-887",
language = "English (US)",
volume = "10",
pages = "887--892",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Cancer immunotherapy

T2 - Breaking the barriers to harvest the crop

AU - Pardoll, Andrew Mark

AU - Allison, James

PY - 2004/9

Y1 - 2004/9

N2 - Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.

AB - Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.

UR - http://www.scopus.com/inward/record.url?scp=4644293572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644293572&partnerID=8YFLogxK

U2 - 10.1038/nm0904-887

DO - 10.1038/nm0904-887

M3 - Article

VL - 10

SP - 887

EP - 892

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 9

ER -